Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly.
Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly.
复制标题
DOI：
10.1016/j.celrep.2023.112991
复制
发表时间：
2023-08
期刊：
影响因子：
8.8
通讯作者：
I. Ferreira;C. Q. Lee;W. Foster;A. Abdullahi;L. Dratva;Z. Tuong;B. Stewart;J. Ferdinand;Stephane M. Guillaume;Martin Potts;Marianne R Perera;Ben Krishna;Ana Ivis Peñalver;Mia Cabantous;S. Kemp;L. Ceron-Gutierrez;S. Ebrahimi;P. Lyons;Ken G. C. Smith;J. Bradley;D. Collier;L. McCoy;A. A. van der Klaauw-A.;James E. D. Thaventhiran;I. Farooqi;Sarah A. Teichmann;P. MacAry;R. Doffinger;M. Wills;M. Linterman;M. Clatworthy;Ravindra K. Gupta
中科院分区：
文献类型：
--
作者：
I. Ferreira;C. Q. Lee;W. Foster;A. Abdullahi;L. Dratva;Z. Tuong;B. Stewart;J. Ferdinand;Stephane M. Guillaume;Martin Potts;Marianne R Perera;Ben Krishna;Ana Ivis Peñalver;Mia Cabantous;S. Kemp;L. Ceron-Gutierrez;S. Ebrahimi;P. Lyons;Ken G. C. Smith;J. Bradley;D. Collier;L. McCoy;A. A. van der Klaauw-A.;James E. D. Thaventhiran;I. Farooqi;Sarah A. Teichmann;P. MacAry;R. Doffinger;M. Wills;M. Linterman;M. Clatworthy;Ravindra K. Gupta
据报道，在老年人中，初次接种疫苗的反应不理想，但关于年龄对加强第三剂反应的影响的信息很少。在这里，我们发现，与年龄小于70岁（中位年龄66岁，范围54-69）的受试者相比，接受AZD 1222初始两剂方案和mRNA疫苗加强第三剂方案的受试者在加强后1个月时对SARS-CoV-2刺突假型病毒的中和抗体应答显著降低。老年人第3次给药后中和效力和宽度受损与表达CD 11 c和FCRL 5的循环“非典型”加标特异性B细胞相关。然而，当考虑接受三剂mRNA疫苗的个体时，我们没有观察到非典型B细胞中和或富集的差异。这项工作突出了AdV和mRNA COVID-19疫苗形式差异指导记忆B细胞反应的发现。
Suboptimal responses to a primary vaccination course have been reported in the elderly, but there is little information regarding the impact of age on responses to booster third doses. Here, we show that individuals 70 years or older (median age 73, range 70–75) who received a primary two-dose schedule with AZD1222 and booster third dose with mRNA vaccine achieve significantly lower neutralizing antibody responses against SARS-CoV-2 spike pseudotyped virus compared with those younger than 70 (median age 66, range 54–69) at 1 month post booster. Impaired neutralization potency and breadth post third dose in the elderly is associated with circulating "atypical" spike-specific B cells expressing CD11c and FCRL5. However, when considering individuals who received three doses of mRNA vaccine, we did not observe differences in neutralization or enrichment in atypical B cells. This work highlights the finding that AdV and mRNA COVID-19 vaccine formats differentially instruct the memory B cell response.